SUMOylation of AMPKα1 by PIAS4 specifically regulates mTORC1 signalling

Nature Communications

Volumn 6, Issue , 2015, Pages

  Yan, Yan ^a   Ollila, Saara ^a   Wong, Iris P L ^a   Vallenius, Tea ^a   Palvimo, Jorma J ^b   Vaahtomeri, Kari ^a   Mäkelä, Tomi P ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 4 HYDROXY 3 (2' HYDROXY 1,1' BIPHENYL 4 YL) 6 OXOTHIENO[2,3 B]PYRIDINE 5 CARBONITRILE; AMP ACTIVATED PROTEIN KINASE ALPHA1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIGASE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PIAS4 LIGASE; UNCLASSIFIED DRUG; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; PIAS4 PROTEIN, HUMAN; PRKAA1 PROTEIN, HUMAN; PROTEIN INHIBITOR OF ACTIVATED STAT; TARGET OF RAPAMYCIN KINASE;

CANCER; CELLS AND CELL COMPONENTS; ENZYME ACTIVITY; FATTY ACID; INHIBITION; MOLECULAR ANALYSIS; PROTEIN; SUBSTRATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER CELL LINE; CANCER GROWTH; CATALYSIS; CELL PROLIFERATION; CONTROLLED STUDY; EMBRYO; ENZYME INACTIVATION; FEMALE; MOUSE; NONHUMAN; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SUMOYLATION; GENETICS; HUMAN; METABOLISM; PHOSPHORYLATION;

AMP-ACTIVATED PROTEIN KINASES; HUMANS; MULTIPROTEIN COMPLEXES; PHOSPHORYLATION; PROTEIN INHIBITORS OF ACTIVATED STAT; SIGNAL TRANSDUCTION; SUMOYLATION; TOR SERINE-THREONINE KINASES;

EID: 84948753909     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms9979     Document Type: Article

References (58)

1. Hardie, D. G., Ross, F. A. & Hawley, S. A. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 13, 251-262 (2012).
2. Mihaylova, M. M. & Shaw, R. J. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat. Cell Biol. 13, 1016-1023 (2011).
3. Xiang, X., Saha, A. K., Wen, R., Ruderman, N. B. & Luo, Z. AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem. Biophys. Res. Commun. 321, 161-167 (2004).
4. Swinnen, J. V. et al. Mimicry of a cellular low energy status blocks tumor cell anabolism and suppresses the malignant phenotype. Cancer Res. 65, 2441-2448 (2005).
5. Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N. & Pollak, M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 66, 10269-10273 (2006).
6. Huang, X. et al. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J. 412, 211-221 (2008).
7. Carling, D., Zammit, V. A. & Hardie, D. G. A common bicyclic protein kinase cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis. FEBS Lett. 223, 217-222 (1987).
8. Shackelford, D. B. & Shaw, R. J. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat. Rev. Cancer. 9, 563-575 (2009).
9. Inoki, K., Zhu, T. & Guan, K. L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115, 577-590 (2003).
10. Gwinn, D. M. et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 30, 214-226 (2008).
11. Kodiha, M., Rassi, J. G., Brown, C. M. & Stochaj, U. Localization of AMP kinase is regulated by stress, cell density, and signaling through the MEK--4ERK1/2 pathway. Am. J. Physiol. Cell Physiol. 293, C1427-C1436 (2007).
12. Kazgan, N., Williams, T., Forsberg, L. J. & Brenman, J. E. Identification of a nuclear export signal in the catalytic subunit of AMP-activated protein kinase. Mol. Biol. Cell 21, 3433-3442 (2010).
13. Stapleton, D. et al. Mammalian AMP-activated protein kinase subfamily. J. Biol. Chem. 271, 611-614 (1996).
14. Salt, I. et al. AMP-activated protein kinase: greater AMP dependence, and preferential nuclear localization, of complexes containing the alpha2 isoform. Biochem. J. 334 (Pt 1), 177-187 (1998).
15. Woods, A., Salt, I., Scott, J., Hardie, D. G. & Carling, D. The alpha1 and alpha2 isoforms of the AMP-activated protein kinase have similar activities in rat liver but exhibit differences in substrate specificity in vitro. FEBS Lett. 397, 347-351 (1996).
16. Oakhill, J. S. et al. b-Subunit myristoylation is the gatekeeper for initiating metabolic stress sensing by AMP-activated protein kinase (AMPK). Proc. Natl Acad. Sci. USA 107, 19237-19241 (2010).
17. Zhou, G. et al. Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation. Mol. Cell 54, 960-974 (2014).
18. Wang, L. & Brautigan, D. L. alpha-SNAP inhibits AMPK signaling to reduce mitochondrial biogenesis and dephosphorylates Thr172 in AMPK alpha in vitro. Nat. Commun. 4, 1559 (2013).
19. Suzuki, T. et al. Inhibition of AMPK catabolic action by GSK3. Mol. Cell 50, 407-419 (2013).
20. Lee, J. O. et al. E3 ubiquitin ligase, WWP1, interacts with AMPKalpha2 and down-regulates its expression in skeletal muscle C2C12 cells. J. Biol. Chem. 288, 4673-4680 (2013).
21. Qi, J. et al. Downregulation of AMP-activated protein kinase by Cideamediated ubiquitination and degradation in brown adipose tissue. EMBO J. 27, 1537-1548 (2008).
22. Costanzo-Garvey, D. L. et al. KSR2 is an essential regulator of AMP kinase, energy expenditure, and insulin sensitivity. Cell Metab. 10, 366-378 (2009).
23. Budanov, A. V. & Karin, M. p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell 134, 451-460 (2008).
24. Lu, J. Y. et al. Acetylation of yeast AMPK controls intrinsic aging independently of caloric restriction. Cell 146, 969-979 (2011).
25. Simpson-Lavy, K. J. & Johnston, M. SUM Oylation regulates the SNF1 protein kinase. Proc. Natl Acad. Sci. USA 110, 17432-17437 (2013).
26. Wilson, M. A. et al. Ubp8 and SAGA regulate Snf1 AMP kinase activity. Mol. Cell Biol. 31, 3126-3135 (2011).
27. Al-Hakim, A. K. et al. Control of AMPK-related kinases by USP9X and atypical Lys(29)/Lys(33)-linked polyubiquitin chains. Biochem. J. 411, 249-260 (2008).
28. Pineda, C. T. et al. Degradation of AMPK by a cancer-specific ubiquitin ligase. Cell 160, 715-728 (2015).
29. Solaz-Fuster, M. C., Gimeno-Alcaniz, J. V., Casado, M. & Sanz, P. TRIP6 transcriptional co-activator is a novel substrate of AMP-activated protein kinase. Cell Signal. 18, 1702-1712 (2006).
30. Banko, M. R. et al. Chemical genetic screen for AMPKalpha2 substrates uncovers a network of proteins involved in mitosis. Mol. Cell 44, 878-892 (2011).
31. Rytinki, M. M., Kaikkonen, S., Pehkonen, P., Jaaskelainen, T. & Palvimo, J. J. PIAS proteins: pleiotropic interactors associated with SUMO. Cell. Mol. Life Sci. 66, 3029-3041 (2009).
32. Corton, J. M., Gillespie, J. G., Hawley, S. A. & Hardie, D. G. 5-aminoimidazole- 4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur. J. Biochem. 229, 558-565 (1995).
33. Santti, H. et al. Disruption of the murine PIASx gene results in reduced testis weight. J. Mol. Endocrinol. 34, 645-654 (2005).
34. Kalender, A. et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 11, 390-401 (2010).
35. Rubio, T., Vernia, S. & Sanz, P. Sumoylation of AMPKbeta2 subunit enhances AMP-activated protein kinase activity. Mol. Biol. Cell. 24, 1801-1811, S1801-S1804 (2013).
36. Laplante, M. & Sabatini, D. M. mTOR signaling in growth control and disease. Cell 149, 274-293 (2012).
37. Sabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P. & Snyder, S. H. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78, 35-43 (1994).
38. Davies, S. P., Carling, D. & Hardie, D. G. Tissue distribution of the AMPactivated protein kinase, and lack of activation by cyclic-AMP-dependent protein kinase, studied using a specific and sensitive peptide assay. Eur. J. Biochem. 186, 123-128 (1989).
39. Bischof, O. et al. The E3 SUMO ligase PIASy is a regulator of cellular senescence and apoptosis. Mol. Cell 22, 783-794 (2006).
40. Soderberg, O. et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat. Methods 3, 995-1000 (2006).
41. Hadad, S. M., Hardie, D. G., Appleyard, V. & Thompson, A. M. Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle. Clin. Transl. Oncol. 16, 746-752 (2014).
42. Cool, B. et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab. 3, 403-416 (2006).
43. Xiao, B. et al. Structural basis of AMPK regulation by small molecule activators. Nat. Commun. 4, 3017 (2013).
44. Scott, J. W. et al. Small molecule drug A-769662 and AMP synergistically activate naive AMPK independent of upstream kinase signaling. Chem. Biol. 21, 619-627 (2014).
45. Noh, W. C. et al. Determinants of rapamycin sensitivity in breast cancer cells. Clin. Cancer Res. 10, 1013-1023 (2004).
46. Guo, D. et al. The AMPK agonist AICAR inhibits the growth of EGFRvIIIexpressing glioblastomas by inhibiting lipogenesis. Proc. Natl Acad. Sci. USA 106, 12932-12937 (2009).
47. Houde, V. P. et al. Investigation of LKB1 Ser431 phosphorylation and Cys433 farnesylation using mouse knockin analysis reveals an unexpected role of prenylation in regulating AMPK activity. Biochem. J. 458, 4156 (2014).
48. Ju, T. C. et al. Nuclear translocation of AMPK-alpha1 potentiates striatal neurodegeneration in Huntingtons disease. J. Cell Biol. 194, 209-227 (2011).
49. Hay, R. T. SUMO: a history of modification. Mol. Cell 18, 1-12 (2005).
50. Yang, W. H. et al. SUMOylation inhibits SF-1 activity by reducing CDK7- mediated serine 203 phosphorylation. Mol. Cell. Biol. 29, 613-625 (2009).
51. Gowans, G. J., Hawley, S. A., Ross, F. A. & Hardie, D. G. AMP is a true physiological regulator of AMP-activated protein kinase by both allosteric activation and enhancing net phosphorylation. Cell Metab. 18, 556-566 (2013).
52. Rytinki, M. M. & Palvimo, J. J. SUMOylation attenuates the function of PGC-1alpha. J. Biol. Chem. 284, 26184-26193 (2009).
53. Tatham, M. H., Rodriguez, M. S., Xirodimas, D. P. & Hay, R. T. Detection of protein SUMOylation in vivo. Nat. Protoc. 4, 1363-1371 (2009).
54. Moilanen, A. M. et al. A testis-specific androgen receptor coregulator that belongs to a novel family of nuclear proteins. J. Biol. Chem. 274, 3700-3704 (1999).
55. Moffat, J. et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124, 1283-1298 (2006).
56. Djouder, N. et al. PKA phosphorylates and inactivates AMPKalpha to promote efficient lipolysis. EMBO J. 29, 469-481 (2010).
57. Klefstrom, J. et al. Induction of TNF-sensitive cellular phenotype by c-Myc involves p53 and impaired NF-kappaB activation. EMBO J. 16, 7382-7392 (1997).
58. Anton, M. & Graham, F. L. Site-specific recombination mediated by an adenovirus vector expressing the Cre recombinase protein: a molecular switch for control of gene expression. J. Virol. 69, 4600-4606 (1995).